Simulations Plus, Inc. (NASDAQ:SLP – Free Report) – Equities research analysts at William Blair raised their Q1 2025 earnings estimates for Simulations Plus in a research report issued on Tuesday, November 5th. William Blair analyst M. Smock now forecasts that the technology company will post earnings of $0.16 per share for the quarter, up from their prior estimate of $0.08. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.11 per share. William Blair also issued estimates for Simulations Plus’ Q2 2025 earnings at $0.27 EPS, Q3 2025 earnings at $0.32 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $1.12 EPS, Q2 2026 earnings at $0.35 EPS, Q3 2026 earnings at $0.40 EPS, Q4 2026 earnings at $0.45 EPS and FY2026 earnings at $1.39 EPS.
Simulations Plus (NASDAQ:SLP – Get Free Report) last issued its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.18 EPS.
Read Our Latest Stock Analysis on Simulations Plus
Simulations Plus Stock Down 0.4 %
NASDAQ:SLP opened at $30.59 on Friday. Simulations Plus has a 52 week low of $27.22 and a 52 week high of $51.22. The company has a market cap of $613.85 million, a PE ratio of 62.43 and a beta of 0.71. The business’s 50 day moving average is $31.60 and its two-hundred day moving average is $39.40.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. First Horizon Advisors Inc. raised its stake in shares of Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares in the last quarter. Mutual of America Capital Management LLC raised its position in shares of Simulations Plus by 18.7% during the 3rd quarter. Mutual of America Capital Management LLC now owns 85,275 shares of the technology company’s stock worth $2,731,000 after buying an additional 13,418 shares in the last quarter. Royce & Associates LP lifted its stake in shares of Simulations Plus by 28.8% in the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after acquiring an additional 53,092 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Simulations Plus by 2.6% in the 3rd quarter. Principal Financial Group Inc. now owns 87,273 shares of the technology company’s stock worth $2,794,000 after acquiring an additional 2,226 shares during the period. Finally, US Bancorp DE boosted its holdings in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after acquiring an additional 1,343 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.
Insider Buying and Selling at Simulations Plus
In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the sale, the director now owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 60,750 shares of company stock valued at $1,905,655 in the last ninety days. Company insiders own 20.90% of the company’s stock.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
See Also
- Five stocks we like better than Simulations Plus
- What is a Stock Market Index and How Do You Use Them?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What does consumer price index measure?
- MarketBeat Week in Review – 11/4 – 11/8
- How to Calculate Return on Investment (ROI)
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.